SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy
BiotechTV - News
00:00
Vlad's reaction to the CRL and patient focus
Vlad Coric explains his surprise at the CRL for Viglyxa and reaffirms commitment to ataxia patients and the published FDA timeline.
Play episode from 00:26
Transcript
